Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Merck & Co., Inc. : WSJ BLOG/Health : Experimental Drug Might Open New Category of Sleep Aid

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/13/2012 | 06:17pm CEST

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)

By Christopher Weaver

Patients with severe insomnia taking a Merck experimental sleep drug drifted off faster and slept longer than those taking placebos in two clinical studies discussed at a Boston sleep conference today.

The drug, suvorexant, opens a new category of sleep drugs by blocking orexin, the brain's chemical emissaries that promote alertness. Merck says it plans to apply for FDA approval later this year.

Both of Merck's trials included more than 1,000 patients with insomnia. Patients whose sleep troubles were caused by other medical problems weren't included in the studies. The results were reported after three months of taking the drug or a placebo.

Those taking suvorexant reported falling asleep 25.7 minutes faster than usual, and sleeping an hour longer in one trial. Merck's researchers also observed patients in sleep labs and determined that patients taking the drug fell asleep 36 minutes faster than usual, while those taking placebos fell asleep 26.6 minutes faster.

The second trial also showed the drug helped people sleep longer, though people in that group who took it didn't fall asleep faster than patients taking placebos.

The findings were presented at the Sleep 2012, an annual meeting of sleep scientists and health providers.

The U.S. market for sleep drugs sagged to $1.85 billion in 2011, down about 8% from the prior year, according to IMS Health, a health-care-information company. The decline was driven by generic competition for key sleep drugs.

Suvorexant could offer a new option for patients with chronic insomnia who routinely need sleeping pills, Merck hopes. Other sleep drugs on the market, such as Ambien, keep patients asleep for about two thirds of the night, while suvorexant provides longer rest, Dr. Darryle Schoepp, Merck's vice president in charge of neuroscience, said in an interview last week.

For decades, a series of sleep drugs have focused on "shutting down the whole brain in maybe a less natural way," Schoepp said. So-called Gaba agonists, such as Ambien, Sonata and Lunesta, which are often prescribed to be taken as needed, have been shown to have side effects, including sleep walking, in a small fraction of patients.

Merck says patients who routinely need sleep aids will better tolerate suvorexant, which also performed well in a cohort of patients Merck followed for a full year. In contrast to older drugs, Schoepp said, Merck's research showed that patients taking suvorexant experienced normal sleep rhythm.

The study showed suvorexant's main side effects were headaches and morning drowsiness.

 
 -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com. 
 

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK AND COMPANY
06:45p MERCK AND : to cut 1,800 U.S. sales jobs, add 960 in chronic care
10/19 ONCOSEC MEDICAL : Initiates Registration Directed Clinical Trial, KEYNOTE-695, o..
10/19 MERCK FOUNDATION : Launches Five-Year Initiative to Improve Diabetes Care for Vu..
10/19DJMERCK AND : Chenault Among Few Black CEOs -- WSJ
10/19 BERGENBIO : Announces Start of PhII Trial Assessing Selective AXL Inhibitor BGB3..
10/18DJMERCK AND : Amex Retirement Shines Light on Lack of Diversity in CEO Ranks
10/18 MERCK AND : U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in M..
10/18 MERCK AND : KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival ..
10/16 ASTRAZENECA : Pharma and medtech industries prepare for hard Brexit
10/16 MERCK AND : Makes $3 Million Charitable Donation to Support Swim Across America
More news
News from SeekingAlpha
01:44p The Market Is Skeptical About Roche Ahead Of Major Trial Read-Outs
12:18p Merck to lay off 1,800 sales reps
04:16a Tracking Ken Fisher's Fisher Asset Management Portfolio - Q3 2017 Update
10/19 WHY ARE THESE 6 DOW STOCKS FAIRLY VA : Part 4 Of 5
10/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : October 19, 2017
Financials ($)
Sales 2017 40 270 M
EBIT 2017 13 680 M
Net income 2017 5 793 M
Debt 2017 8 103 M
Yield 2017 2,96%
P/E ratio 2017 31,81
P/E ratio 2018 18,99
EV / Sales 2017 4,52x
EV / Sales 2018 4,44x
Capitalization 174 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 70,0 $
Spread / Average Target 9,7%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY7.88%173 214
JOHNSON & JOHNSON23.29%377 585
NOVARTIS13.50%226 453
ROCHE HOLDING LTD.5.55%215 760
PFIZER11.58%213 372
AMGEN27.41%135 924